Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Magnus Life Science

Request full access

Magnus has those ideas and employs a novel approach to the advancement and rapid development of valuable new discoveries in biomedicine

London, United KingdomFounded 2013Biotech & Life Sciences

About Magnus Life Science

Magnus Life Science, founded in 2013 by John Martin, operated as a London-based biomedical company focused on translating scientific research into therapeutic solutions. The firm was strategically based at University College London (UCL) to foster a close collaboration between commercially-driven scientists and academic researchers, with Professor John Martin, Chair of Cardiovascular Medicine at UCL, also serving as the company's Chief Scientist. The company's business model was centered on a "spin-in" approach, where it would acquire therapeutic assets and establish each as a distinct company, granting share ownership to the founding scientists.

Magnus Life Science successfully raised approximately $25 million (£15.5 million) in seed funding from a private equity investor, which was supplemented by €11.5 million in grants from the European Commission's Framework 7 (FP7) program for two of its key initiatives. The company's diverse research and development portfolio was unified by a central focus on understanding blood flow to treat a range of diseases. This portfolio was structured into several subsidiary programs, each targeting a high-unmet medical need. These included Magnus Oxygen, which was developing an injectable therapy to prevent reperfusion injury and chronic heart failure. Magnus Flow focused on a bio-magnetic and biodegradable stent for treating coronary artery stenosis. Other programs were Magnus Growth, aimed at therapies for placental insufficiencies; Magnus Life, developing small molecule immunotherapies for cancer; and Magnus Metabolic, which targeted the cardiovascular effects of Type II Diabetes and obesity. Despite its promising start and funding, the company is now reported as deadpooled.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Hard Tech, DT and LS, uk is8 life sciences, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Oct 2014 $20M $82M Undisclosed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Magnus Life Science website traffic

Latest recorded traffic for Magnus Life Science is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Magnus Life Science in the London ecosystem

Live from Dealroom

The Magnus Life Science office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · London HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Magnus Life Science on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Magnus Life Science’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.